Meat consumption, nonsteroidal anti-inflammatory drug use, and mortality among colorectal cancer patients in the California teachers study

Cancer Prevention Research

Volumn 3, Issue 7, 2010, Pages 865-875

  Zell, Jason A ^a,b   Ziogas, Argyrios ^a   Bernstein, Leslie ^c   Clarke, Christina A ^d   Deapen, Dennis ^e   Largent, Joan A ^a   Neuhausen, Susan L ^c   Stram, Daniel O ^e   Ursin, Giske ^e   Anton Culver, Hoda ^a  

^a Genetic Epidemiology Research Institute   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^d CANCER PREVENTION INSTITUTE OF CALIFORNIA   (United States)

^e UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANACIN; EXCEDRIN; IBUPROFEN; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER PATIENT; CANCER SURVIVAL; COLORECTAL CARCINOMA; CONTROLLED STUDY; DIETARY INTAKE; DRUG USE; FEMALE; FOOD INTAKE; HUMAN; MAJOR CLINICAL STUDY; MEAT; PRIORITY JOURNAL; QUESTIONNAIRE;

ADULT; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; CALIFORNIA; COLORECTAL NEOPLASMS; DIET; EATING; FEMALE; HUMANS; IBUPROFEN; MEAT; MIDDLE AGED; RISK FACTORS;

EID: 77954713636     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-09-0262     Document Type: Article

References (52)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics. CA Cancer J Clin 2009;59:225-49.
2. Reddy BS, Maruyama H, Kelloff G. Dose-related inhibition of colon carcinogenesis by dietary piroxicam, a nonsteroidal antiinflammatory drug, during different stages of rat colon tumor development. Cancer Res 1987;47:5340-6. (Pubitemid 17152943)
3. Boolbol SK, Dannenberg AJ, Chadburn A, et al. Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis. Cancer Res 1996;56:2556-60.
4. Barnes CJ, Lee M. Chemoprevention of spontaneous intestinal adenomas in the adenomatous polyposis coli Min mouse model with aspirin. Gastroenterology 1998;114:873-7.
5. Chan AT, Giovannucci EL, Schernhammer ES, et al. A prospective study of aspirin use and the risk for colorectal adenoma. Ann Intern Med 2004;140:157-66.
6. Chan AT, Giovannucci EL, Meyerhardt JA, Schernhammer ES, Curhan GC, Fuchs CS. Long-term use of aspirin and nonsteroidal anti-inflammatory drugs and risk of colorectal cancer. JAMA 2005;294:914-23.
7. Jacobs EJ, Thun MJ, Bain EB, Rodriguez C, Henley SJ, Calle EE. A large cohort study of long-term daily use of adult-strength aspirin and cancer incidence. J Natl Cancer Inst 2007;99:608-15.
8. Baron JA, Cole BF, Sandler RS, et al. A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 2003;348:891-9.
9. Sandler RS, Halabi S, Baron JA, et al. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med 2003;348:883-90.
10. Giovannucci E, Rimm EB, Stampfer MJ, Colditz GA, Ascherio A, Willett WC. Aspirin use and the risk for colorectal-cancer and adenoma in male health-professionals. Ann Intern Med 1994;121:241-6.
11. Fuchs C, Meyerhardt JA, Heseltine DL, et al. Influence of regular aspirin use on survival for patients with stage III colon cancer: findings from Intergroup trial CALGB 89803. J Clin Oncol, 2005 ASCO Annual Meeting Proceedings 2005;23:3530.
12. Zell JA, Ziogas A, Bernstein L, et al. Nonsteroidal anti-inflammatory drugs: effects on mortality after colorectal cancer diagnosis. Cancer 2009;115:5662-71.
13. Chan AT, Ogino S, Fuchs CS. Aspirin use and survival after diagnosis of colorectal cancer. JAMA 2009;302:649-58.
14. Meyerhardt JA, Niedzwiecki D, Hollis D, et al. Association of dietary patterns with cancer recurrence and survival in patients with stage III colon cancer. JAMA 2007;298:754-64.
15. Zell JA, Ignatenko NA, Yerushalmi HF, et al. Risk and risk reduction involving arginine intake and meat consumption in colorectal tumor-igenesis and survival. Int J Cancer 2007;120:459-68.
16. Gerner EW. Impact of dietary amino acids and polyamines on intestinal carcinogenesis and chemoprevention in mouse models. Biochem Soc Trans 2007;35:322-5.
17. Yerushalmi HF, Besselsen DG, Ignatenko NA, et al. The role of NO synthases in arginine-dependent small intestinal and colonic carcinogenesis. Mol Carcinog 2006;45:93-105.
18. Anton-Culver H, Zell JA, Yerushalmi H, Ziogas A, Gerner EW. Effects of non-steroidal anti-inflammatory drugs and meat intake on survival in colorectal carcinoma patients. AACR Colorectal Cancer: Molecular Pathways and Therapies - Conference Proceedings, Dana Point (CA). Oct 19-23, 2005. Oral Presentation: Session 8 - Epidemiology and Prevention II.
19. Bernstein L, Allen M, Anton-Culver H, et al. High breast cancer incidence rates among California teachers: results from the California Teachers Study (United States). Cancer Causes Control 2002;13:625-35.
20. Kwong S, Perkin C, Morris C, Cohen R, Allen M, Wright W. Cancer in California: 1988-1999. Sacramento (CA): California Department of Health Services, Cancer Surveillance Section; 2001.
21. Young J, Roffers SD, Ries LAG, Fritz AG, Hurlbut AA. SEER summary staging manual - 2000: codes and coding instructions. Bethesda (MD): National Cancer Institute, NIH Pub. No. 01-4969; 2001.
22. Fritz A, Percy C, Jack A, Shanmugaratnam K, Parkin DM, Whelan S. International Classification of Diseases for Oncology. 3rd ed. Geneva: WHO; 2000.
23. Block G, Woods M, Potosky A, Clifford C. Validation of a self-administered diet history questionnaire using multiple diet records. J Clin Epidemiol 1990;43:1327-35.
24. Horn-Ross PL, Hoggatt KJ, West DW, et al. Recent diet and breast cancer risk: the California Teachers Study (USA). Cancer Causes Control 2002;13:407-15.
25. Yost K, Perkins C, Cohen R, Morris C, Wright W. Socioeconomic status and breast cancer incidence in California for different race/ethnic groups. Cancer Causes Control 2001;12:703-11.
26. Rostom A, Dube C, Lewin G, et al. Nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors for primary prevention of colorectal cancer: a systematic review prepared for the U.S. Preventive Services Task Force. Ann Intern Med 2007;146:376-89.
27. Chan AT, Ogino S, Fuchs CS. Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. N Engl J Med 2007;356:2131-42.
28. 1-acetyltransferase (SSAT) by aspirin in Caco-2 colon cancer cells. Biochem J 2006;394:317-24.
29. Babbar N, Ignatenko NA, Casero RA, Jr., Gerner EW. Cyclooxygenase- independent induction of apoptosis by sulindac sulfone is mediated by polyamines in colon cancer. J Biol Chem 2003;278:47762-75.
30. Gerner EW, Meyskens FL, Jr. Polyamines and cancer: old molecules, new understanding. Nat Rev Cancer 2004;4:781-92.
31. Thomas T, Thomas TJ. Polyamine metabolism and cancer. J Cell Mol Med 2003;7:113-26.
32. Zoumas-Morse C, Rock CL, Quintana EL, Neuhouser ML, Gerner EW, Meyskens FL, Jr. Development of a polyamine database for assessing dietary intake. J Am Diet Assoc 2007;107:1024-7.
33. Venho B, Voutilainen S, Valkonen VP, et al. Arginine intake, blood pressure, and the incidence of acute coronary events in men: the Kuopio Ischaemic Heart Disease Risk Factor Study. Am J Clin Nutr 2002;76:359-64.
34. Wu G, Morris SM, Jr. Arginine metabolism: nitric oxide and beyond. Biochem J 1998;336:1-17.
35. Zell JA, Ziogas A, Ignatenko N, et al. Associations of a polymorphism in the ornithine decarboxylase gene with colorectal cancer survival. Clin Cancer Res 2009;15:6208-16.
36. Martinez ME, O'Brien TG, Fultz KE, et al. Pronounced reduction in adenoma recurrence associated with aspirin use and a polymorphism in the ornithine decarboxylase gene. Proc Natl Acad Sci U S A 2003;100:7859-64.
37. Barry ELR, Baron JA, Bhat S, et al. Ornithine decarboxylase polymorphism modification of response to aspirin treatment for colorectal adenoma prevention. J Natl Cancer Inst 2006;98:1494-500.
38. Hubner RA, Muir KR, Liu JF, Logan RF, Grainge MJ, Houlston RS. Ornithine decarboxylase G316A genotype is prognostic for colorectal adenoma recurrence and predicts efficacy of aspirin chemoprevention. Clin Cancer Res 2008;14:2303-9.
39. Meyskens FL, Jr., McLaren CE, Pelot D, et al. Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial. Cancer Prev Res 2008;1:32-8.
40. McLaren CE, Fujikawa-Brooks S, Chen WP, et al. Longitudinal assessment of air conduction audiograms in a phase III clinical trial of difluoromethylornithine and sulindac for prevention of sporadic colorectal adenomas. Cancer Prev Res 2008;1:514-21.
41. Zell JA, Pelot D, Chen WP, McLaren CE, Gerner EW, Meyskens FL. Risk of cardiovascular events in a randomized placebo-controlled, double-blind trial of difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas. Cancer Prev Res 2009;2:209-12.
42. Raj KP, Zell JA, Rock CL, et al. Role of dietary polyamines in a phase III clinical trial of DFMO and sulindac for prevention of metachronous colorectal adenomas: a potential target for colon cancer chemoprevention. Gastrointestinal Cancers Symposium; January 22-24, 2010, Orlando (FL). Abstract ID# 279.
43. Norat T, Lukanova A, Ferrari P, Riboli E. Meat consumption and colorectal cancer risk: dose-response meta-analysis of epidemiological studies. Int J Cancer 2002;98:241-56.
44. Wakabayashi K, Nagao M, Esumi H, Sugimura T. Food-derived mutagens and carcinogens. Cancer Res 1992;52:2092s-8s.
45. Ito N, Hasegawa R, Sano M, et al. A new colon and mammary carcinogen in cooked food, 2-amino-1-methyl-6-phenylimidazo[4,5-b] pyridine (PhIP). Carcinogenesis 1991;12:1503-6.
46. Sinha R, Kulldorff M, Chow WH, Denobile J, Rothman N. Dietary intake of heterocyclic amines, meat-derived mutagenic activity, and risk of colorectal adenomas. Cancer Epidemiol Biomarkers Prev 2001;10:559-62. (Pubitemid 32701644)
47. Ravoori S, Feng Y, Neale JR, et al. Dose-dependent reduction of 3,2′-dimethyl-4-aminobiphenyl-derived DNA adducts in colon and liver of rats administered celecoxib. Mutat Res 2008;638:103-9.
48. Sinha R, Cross A, Curtin J, et al. Development of a food frequency questionnaire module and databases for compounds in cooked and processed meats. Mol Nutr Food Res 2005;49:648-55.
49. Wray CM, Ziogas A, Hinojosa MW, Le H, Stamos MJ, Zell JA. Tumor subsite location within the colon is prognostic for survival after colon cancer diagnosis. Dis Colon Rectum 2009;52:1359-66.
50. Zell JA, Honda J, Ziogas A, Anton-Culver H. Survival after colorectal cancer diagnosis is associated with colorectal cancer family history. Cancer Epidemiol Biomarkers Prev 2008;17:3134-40.
51. S0820, "A double-blind placebo-controlled trial of eflornithine and sulindac to prevent recurrence of high risk adenomas and second primary colorectal cancers in patients with stage 0-III colon cancer." Southwest Oncology Group Fall 2009 Group Meeting Agenda: Available at: https://swog.org/Visitors/Fall09GpMtg/0910Agenda.pdf, page 37; last accessed Feb. 1, 2010.
52. 80702 A phase III trial of 6 versus 12 treatments of adjuvant FOLFOX with or without celecoxib therapy for patients with stage III colon cancer. Cancer and Leukemia Group B Summer 2009 Agenda Book: Available at: http://www.calgb. org/Public/meetings/meeting-documents/2009/summer-group/AgendaBook-062009.pdf, page 7; last accessed Feb. 1, 2010.